The FDA has granted a priority review for the evaluation of Xtandi as a treatment for patients with non-metastatic castration-sensitive prostate cancer. The Food and Drug Administration (FDA) has ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback